Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer.
AuthorsWang, Lai Mun
AffiliationDepartment of Histopathology & Centre for Colorectal Disease, St Vincent's, University Hospital, Dublin, Ireland.
Aged, 80 and over
Cytological Techniques/*methods/statistics & numerical data
MetadataShow full item record
CitationAm J Surg Pathol. 2009 Jan;33(1):134-41.
JournalThe American journal of surgical pathology
AbstractBACKGROUND: Tumor budding along the advancing front of colorectal adenocarcinoma is an early event in the metastatic process. A reproducible, prognostic budding scoring system based on outcomes in early stage colorectal cancer has not been established. DESIGN: One hundred twenty-eight T3N0M0 colorectal carcinoma patients with known outcome were identified. Tumor budding was defined as isolated tumor cells or clusters of <5 cells at the invasive tumor front. Tumor bud counts were generated in 5 regions at 200x by 2 pathologists (conventional bud count method). The median bud count per case was used to divide cases into low (median=0) and high budding (median > or =1) groups. Forty cases were reevaluated to assess reproducibility using the conventional and a novel rapid bud count method. RESULTS: Fifty-seven (45%) carcinomas had high and 71 (55%) had low budding scores. High budding was associated with an infiltrative growth pattern (P<0.0001) and lymphovascular invasion (P=0.005). Five-year cancer-specific survival was significantly poorer in high compared with low budding groups: 63% versus 91%, respectively, P<0.0001. Multivariate analysis demonstrated tumor budding to be independently prognostic (hazard ratio=4.76, P<0.001). Interobserver agreement was at least equivalent comparing the conventional to the rapid bud count methods: 87.5% agreement (kappa=0.75) versus 92.5% agreement (kappa=0.85), respectively. CONCLUSIONS: Tumor budding is a strong, reproducible, and independent prognostic marker of outcome that is easily assessed on hematoxylin and eosin slides. This may be useful for identifying the subset of T3N0M0 patients at high risk of recurrence who may benefit from adjuvant therapy.
- Aggressive colorectal carcinoma phenotypes of invasion can be assessed reproducibly and effectively predict poor survival: interobserver study and multivariate survival analysis of a prospectively collected series of 299 patients after potentially curative resections with long-term follow-up.
- Authors: Wöhlke M, Schiffmann L, Prall F
- Issue date: 2011 Nov
- Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer.
- Authors: Karamitopoulou E, Zlobec I, Kölzer V, Kondi-Pafiti A, Patsouris ES, Gennatas K, Lugli A
- Issue date: 2013 Feb
- Pathologic determinants of survival after resection of T3N0 (Stage IIA) colorectal cancer: proposal for a new prognostic model.
- Authors: Cianchi F, Messerini L, Comin CE, Boddi V, Perna F, Perigli G, Cortesini C
- Issue date: 2007 Sep
- Tumor budding as an index to identify high-risk patients with stage II colon cancer.
- Authors: Nakamura T, Mitomi H, Kanazawa H, Ohkura Y, Watanabe M
- Issue date: 2008 May
- Prognostic significance of CXCL12 expression in patients with colorectal carcinoma.
- Authors: Akishima-Fukasawa Y, Nakanishi Y, Ino Y, Moriya Y, Kanai Y, Hirohashi S
- Issue date: 2009 Aug